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Abstract: Small cell lung cancer (SCLC) is a very aggressive cancer with poor outcome if left untreated, but it is also one of the most 
chemotherapy responsive cancers. Overall it has a very poor prognosis especially if it is chemotherapy resistant to first line treatment. 
Second line chemotherapy has not been very beneficial in SCLC as opposed to breast cancer and lymphoma. In the last few years 
topotecan is the only drug that has been approved by the food and drug administration (FDA) for the second line treatment of SCLC 
but in Japan another drug, amrubicin is approved. There are many combinations of different chemotherapies available in moderate to 
high intensity, in this difficult to treat patient to overcome the chemo resistance, but many of these studies are small or phase II trials. 
In this article we have reviewed single agent and multidrug regimens that were studied in both chemo sensitive and refractory setting, 
including the most recent clinical trials.
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Introduction and Background
Lung cancer is the leading cause of cancer related 
  mortality  in  US.1  Small  cell  lung  cancer  (SCLC) 
which is the second most common type after non-
small cell lung cancer (NSCLC), is almost always 
seen in patients with history of smoking and is gener-
ally very chemotherapy sensitive. Most SCLC patients 
are present with systemic disease with both micro and 
macro metastatic deposits. It is one of the most com-
mon cancers than can cross the blood brain barrier 
with frequent metastasis to the brain. In one report, 
approximately 18% of patients were found to have 
brain metastasis at time of diagnosis and the 2-year 
cumulative risk of brain metastasis reached 49% for 
patients with limited disease and 65% for patients 
with extensive disease, this can go up to 80% after 
two years of survival.2 For this reason we screen all 
patients with brain imaging at the time of diagnosis 
and use prophylactic cranial irradiation (PCI) as part 
of their treatment, for those without brain metastasis.
In recent years, incidence of  this disease has dropped 
dramatically as shown by SEER data mainly because 
of drop in tobacco use in the last few decades or per-
haps because of the change in cigarette composition.3 
Proportion of  SCLC of all lung cancers decreased from 
17.26% in 1986 to 12.95% in 2002. Of all patients 
with SCLC, the proportion of women with SCLC has 
increased from 28% in 1973 to 50% in 2002.3 SCLC is 
staged either as limited stage or extensive stage. Lim-
ited disease (LD) is confined to one hemi-thorax (but 
may include contra lateral mediastinal lymph node), 
without pleural or pericardial effusion which can be 
encompassed in one radiation port. Disease not meet-
ing  these  criteria  is  called  extensive  disease  (ED). 
About 30% of SCLC patients are present with LD and 
80%–90% of these respond to combination chemother-
apy with radiation. In turn 40%–70% achieve complete 
remission, with median survival of 12–20 months, and 
two and five year survival of 20%–40% and 5%–10%, 
respectively. Extensive stage is present at diagnosis in 
more than 60%–70% of cases, and median survival 
for such patients is about 9.3 months, while 5-yr sur-
vival is 2% and 1% at ten years.4
Current standard of care for limited stage is plati-
num based chemotherapy with radiation and for exten-
sive stage is platinum based chemotherapy alone. In 
both stages if patient has had at least a partial response 
they should be offered PCI, as it has shown to   prolong 
overall survival.5 Unfortunately, even though we can get 
  complete response (CR) or partial response (PR) in 
most patients, majority of  these will relapse and die of   
their disease. Options for refractory or relapsed disease 
depend on the patient’s overall general condition, sensitiv-
ity to first line chemotherapy and duration of remission.
Relapsed scLc
Although initially SCLC is very chemotherapy sen-
sitive,  many  patients  tend  to  relapse.  Majority  of 
the patients relapse (about 80% with LD and almost 
all with ED).6 If they relapse within 60–90 days of 
treatment,  they  are  called  chemotherapy  refractory 
as opposed to chemotherapy sensitive patients who 
relapse after this time. Patients who are chemotherapy 
refractory tend to have a poor overall survival, with 
response rate to further chemotherapy being around 
10% or less, but for chemo sensitive patients it can be 
up to 25%.7 Studies have shown that 2nd line treatment 
can give significant palliation in these patients.8,9
Treatment Options for Relapsed scLc
We have very few treatment options to improve sur-
vival  over  best  supportive  care.8,9  Topotecan  and 
amrubicin are two agents currently in use for relapsed 
SCLC. Topotecan is approved in US and amrubicin is 
approved only in Japan.
Re-induction
As in any other tumor, if patients are sensitive to first 
line chemotherapy and are able to tolerate it, we can 
always use the same treatment with good response 
rate. The most important factor in predicting future 
response is the duration of first response.10 A retrospec-
tive multi institutional analysis on outcomes of small 
cell lung cancer with second line chemotherapy involv-
ing 161 patients showed an overall response rate of 
22.2%. Response rate was better for platinum sensitive 
patients who are re-challenged with platinum based che-
motherapy as opposed to platinum refractory (34.5% 
vs.17.5%). OS (overall survival) was also better in these 
patients 9.2 vs. 5.8 months respectively. In this study, 
response to first line treatment and performance status 
(PS) were the only independent prognostic factors.11
Topotecan Based Treatments
Topotecan, a water soluble semi synthetic   derivative of 
camptothecin is a specific inhibitor of   topoisomerase I, pharmacotherapies for the treatment of SCLC
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and is the most studied drug in relapsed SCLC. In a 
phase II study by Ardizzoni et al involving 92 patients 
reported a response rate of 6.4% in refractory and 
37.8% in sensitive disease, with dose of 1.5 mg/m2 for 
five consecutive days every three weeks.12 Treat et al 
retrospectively analyzed data from five clinical trials 
that included 479 patients who were treated with sin-
gle agent topotecan, had ORR (overall relapse rate) of 
14% with eleven complete responses among good PS 
patient, but it was 17% with three CR in patients with 
PS two. In sub analysis, chemotherapy sensitive and 
refractory patients responded about the same regard-
less of their PS, good PS had ORR of 18% and 3% but 
in poor PS it was 24% and 3%, respectively. Treatment 
benefited patients regardless of PS, with median over-
all survival of 36.3 weeks, 25.4 weeks, and 16 weeks 
for PS 0, 1, and 2 patients, respectively. Major toxic-
ity was hematological in about 42% of patients and 
febrile neutropenia occurred in 3% or 4% depending 
on the PS and treatment related death occurred in 8% 
of patients.13 This retrospective analysis suggests that 
topotecan has clinical benefit mainly among chemo sen-
sitive patients even if they have poor PS. (See Table 1).
Intravenous versus oral topotecan
Some  patients  prefer  to  take  PO  drugs  especially 
if they can avoid IV lines and frequent clinic vis-
its.  Eckardt  et  al  did  an  open  label,  randomized, 
phase III study comparing oral and IV topotecan in 
patients with SCLC sensitive to initial chemotherapy 
on 309 patients, included both chemo refractory and 
sensitive  patients.  Treatment  with  oral  topotecan 
(2.3 mg/m2/d) on days one through five or IV topotecan 
(1.5 mg/m2/d) on days one through five every 21 days 
was given. Patients who received this regimen had 
median OS of 33.0 weeks and 35 weeks respectively. 
Oral topotecan had one and two year survival rates of 
32.6% and 12.4% and for IV topotecan it was 29.2% 
and 7.1% respectively. Major toxicities were grade 4 
neutropenia and thrombocytopenia in 47% and 29% 
in PO group and 64% and 18% in IV treatment group 
respectively. Other side effects included nausea (43% 
oral, 42% IV), fatigue (31% oral, 36% IV), and diar-
rhea (36% oral, 20% IV). This study showed that oral 
topotecan can be given to these patients with manage-
able toxicity instead of IV if needed.14 A systematic 
review to look at economical stand point and clinical 
benefit by Hartwell et al showed that oral topotecan 
for patients with relapsed disease was associated with 
improved outcome and four months gain of life, but 
with increased cost.15
Oral topotecan versus best  
supportive care
It is always important to determine if giving chemo-
therapy or supportive care to the patient is better due to 
side effects, cost, and the follow up needed for chemo-
therapy. This question was answered in a randomized 
controlled phase III trial by O’ Brien et al involving 
141 patients with relapsed SCLC patients, who were 
not candidates for standard IV chemotherapy. They 
were randomized between best supportive care (BSC) 
or oral topotecan (2.3 mg/m2/d), days one through 
five, every 21 days. They reported median overall 
Table 1. Topotecan based treatment as second line for small cell lung cancer.
phase, drug Authors number ORR % TTp Os TRD
II, topotecan 
(Iv)
Ardizzoni12 92 (S+r) S-37.9 
r-6.4
7.6 m S-6 m 
r-4.7 m
None
II, topotecan 
(Iv)
perez-Soler63 32 (r) r-11 – 20 w None
II, topotecan 
(Iv)
Depierre A64 9 (S+r) S-14 
r-2.4
 
–
S-25.7 w 
r-16.3 w
3%
III, topotecan 
(Iv vs. pO)
Eckardt14 309 (S) Oral-18.3 
Iv-21.9
– 33 w 
35 w
None
III, toptecan 
(pO vs. BSC)
O’Brien8 141 T-7 – T-25.9 w 
BSC-13.9 w
6%
III, topotecan 
(Iv vs. CAv)
von pawel9 211 (S) T-24.3 
CAv-18.3
– 25 w 
24.7 w
Abbreviations: S, sensitive; r, refractory; BSC, best supportive care; T, topotecan; CAv, cyclophosphamide adryamicin and vincristine; w, week;   
M, month; Orr, over all response rate; TTp, time to progression; TrD, treatment related death; OS, overall survival.Nair et al
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survival of 25.9 weeks and 13.9 weeks, among oral 
  topotecan  and  best  supportive  care  respectively 
(P = 0.01). Response rate was not unexpected, 7% 
had partial response and 44% had stable disease in 
topotecan group. Those who received topotecan had 
better quality of life and slower deterioration. Over-
all toxic deaths occurred in 6% of the patients in the 
topotecan arm. Mortality rate within 30 days of che-
motherapy were 13% in topotecan and 7% in BSC 
group. This study provides evidence for use of topo-
tecan instead of best supportive care if patient agrees 
and are able to afford the cost. Especially since it can 
help with clinical symptoms and can prolong their 
life by few weeks.8
weekly topotecan
Many doses and schedules of topotecan have been 
investigated to see if they have similar clinical benefit 
with improved side effects profile or more convenient. 
Weekly treatment is an option in ovarian cancer, and 
this approach was investigated in SCLC as well. So 
far we do not have enough clinical studies to answer 
this question. Shipley et al did a phase II study, and pre-
sented an abstract regarding 103 patients with SCLC 
who  had  sensitive  and  resistant  relapsed  disease 
and received topotecan (4 mg/m2) IV over 30 minutes 
weekly for twelve weeks. ORR was 13 and 3% in sen-
sitive and resistant patients, respectively. This study 
showed similar response rate when compared to his-
torical data and was considerably less   myelotoxic.16 
However,  in  another  published  phase  II  study  on 
weekly topotecan, (4 mg/m2) IV on days 1, 8 and 15 
every four weeks, patients who had one prior chemo-
therapy did not show any clinical benefit. None of the 
patients responded to topotecan and four had stable 
disease.17 Since these two studies are conflicting and 
no phase III studies published, it is not a favorable 
option at this time.
Topotecan vs. CAv
Some patients are still able to take multi drug regi-
ments when they relapse therefore it is important to 
know if single agent is equal, worst or better than 
combination. In a large randomized controlled clini-
cal trial with 211 patients, single agent topotecan was 
compared with doxorubicin, cyclophosphamide, and 
vincristine (CAV) in patients with chemo sensitive dis-
ease. Patients received either   topotecan (1.5 mg/m2) as 
a 30-minute infusion daily for five days every 21 days 
or CAV (cyclophosphamide 1,000 mg/m2, doxorubicin 
45 mg/m2, and vincristine 2 mg) infused on day one 
every 21 days. Response rate was 24.3% and 18.3% 
for  topotecan  and  CAV,  respectively  (P  =  0.285). 
Interestingly, their medial survival was very similar 
with 25 weeks for topotecan and 24.7 weeks for CAV 
(P = 0.795). Importantly, topotecan gave better symp-
tom control compared to CAV. Major toxicities included 
grade 4 neutropenia seen in 37.8% of topotecan arm 
versus 51.4% of CAV arm (P , 0.001). But Grade 4 
thrombocytopenia and grade 3 or 4 anemia occurred 
in 8% and 17.7% of topotecan group but among CAV 
ground it was only 1.4% and 7.2%. (P , 0.001).9 
This study established topotecan as the first choice in 
relapsed SCLC (if they are chemo sensitive to 1st line 
treatment) especially since it has shown to improve 
symptoms as compared to multi agent chemotherapy 
with manageable side effects.
Low dose topotecan
Lower-dose topotecan regimens have been evaluated 
in an attempt to minimize hematologic toxicities and 
to maintain efficacy. In a phase II study by Koschel 
et al, low dose topotecan IV (1.25 mg/m2) on days one 
to five of a 21 day cycle in patients with SCLC reported 
overall response rate of 15% and median OS of 22.4 
weeks which was similar to results reported in studies 
using the standard regimen.18 Tadeka et al in another 
phase II trial in Japan on 53 patients who were admin-
istered much lower dose of topotecan (1.0 mg/m2/day) 
for five consecutive days every three weeks in relapsed 
SCLC patients. Notable major toxicity was grade 4 
neutropenia (24%) thrombocytopenia (5%) and anemia 
(3%). They reported an overall response rate of 26% 
(26% PR and 42% SD) with median progression free 
survival of 4.3 and OS of 8.6 months.19   Perez-Soler 
et al tried (1.25 mg/m2) IV on patients refractory to 
platinum  based  treatment  and  showed  a  response 
rate of 11% partial 7% minor and 17% stable dis-
ease, they included 32 patients for this study. Grade 3 
and 4 neutropenia and thrombocytopenia were 70% 
and 31% respectively.63 These trials were very inter-
esting since they showed similar response rate and 
better  side  effect  profile  than  historical  data.  But 
these  doses  have  not  been  validated  in  phase  III 
trials. From these three studies, we can conclude that 
low-dose topotecan therapy may be appropriate for pharmacotherapies for the treatment of SCLC
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patients who exhibit risk factors for treatment-related 
  myelosuppression such as advanced age, extensive 
past treatment, or renal impairment.20
Topotecan combinations  
in Relapsed scLc
To improve clinical response of topotecan it has been 
studied in combination with other chemotherapeutic 
agents in relapsed and refractory setting.
Topotecan and platinum agents
Historically, platinums have been key drugs for combi-
nations. Topotecan in combination with cisplatin was 
studied in a phase II trial involving 110 patients with 
chemotherapy sensitive(s) and refractory(r) relapsed 
SCLC. Patients were given cisplatin (60 mg/m2) on day 
one and topotecan daily IV infusion at (0.75 mg/m2) 
from days one to five every three weeks. Chemosen-
stive  patients  had  better  response  rate  of  29.4% 
and  surprisingly  RR  for  chemo  refractory  patients 
was 23.8%.
Main  toxicity  included  myelosupression  with 
grade  4  neutropenia  in  62%  and  49%  along  with 
grade 4 thrombocytopenia in 54% and 44% in sen-
sitive  and  refractory  patients  respectively.  Neutro-
penic fever occurred in 19% of sensitive patients and 
in 15% of refractory patients and five patients died 
from treatment related toxicity. Median OS was very 
similar with 6.6 months and 6.1 months in each group 
respectively.21 In an another study with 34 patients 
who were treated with much lower dose of cispla-
tin (20 mg/m2) and topotecan (0.9 mg/m2) given on 
days 1–3 every three weeks. Overall response rate 
was 18% in chemo sensitive and 8% in chemo refrac-
tory patients. Median OS was 7.8 and 6.2 months 
for each group respectively. Major side effects were 
myelosupression, much lower than above study, and 
no toxic death related to treatment, they were grade 
3–4  anemia  (15%),  thrombocytopenia  (15%)  and 
neutropenia (42%).22   Carboplatin was also tried in 
combination with topotecan, phase I study of topote-
can 0.85 mg/m2, on days one to five and carboplatin 
area under curve 5 every three weeks showed a partial 
response of 17.2% and median OS of 11 months.23 
It is important to note from these studies about the 
response rate on chemo refractory patients and over-
all survival and this combination is an option in both 
chemo sensitive and chemo refractory patients.
Topotecan and vincristine
This combination was studied in eighteen patients who 
relapsed after carboplatin and etoposide. Topotecan 
(1.5 mg/m2) IV on days 1–3 and vincristine (1 mg) IV 
on either days 1, 3 or days 1, 4 every 21 days were 
given. This regimen gave an overall response rate of 
19% with median OS of five months. The treatment 
was well tolerated. Patients had manageable toxicities 
including Grade 3 and 4 neutropenia (31%), anemia 
(38%) and thrombocytopenia (50%).24
weekly topotecan and gemcitabine
To see if there can be improvement upon single agent 
topotecan there was a phase II study of combinations 
of this drug with gemcitabine by Domine et al from 
Spain. Their regimen included topotecan at dose of 
(4 mg/m2) IV on days one and eight, and gemcitabine 
(1,250  mg/m2)  on  days  one  and  eight  every  three 
weeks, gave a RR of 12%. They concluded that add-
ing gemcitabine to topotecan does not improve effi-
cacy of topotecan.25
Overall, these studies showed that topotecan is an 
active agent in relapsed SCLC and better in chemo 
sensitive patients. Adding second chemotherapy agent 
to topotecan may or may not have additional benefit, 
but certainly gives more toxicity to these patients. 
It is possible that combination with platinums work 
due  to  synergism  with  topotecan  as  compared  to 
gemcitabine.
Amrubicin Based Treatments  
a new Hope
Amrubicin is a synthetic anthracycline and its structure 
is based on doxorubicin in which the hydroxyl group 
at position 9 has been replaced by an amino group to 
enhance its efficacy. In vivo, studies showed amrubi-
cin has more potent antitumor effects and lower toxic 
effects on the heart, liver and kidneys as compared 
to doxorubicin. This drug is schedule dependant as 
better  antitumor  effect  is  seen  with  administration 
over five days. It acts on topoisomerase II, stabilizing 
a cleavable complex.26 It has been extensively evalu-
ated in Japan, where it is approved for patients with 
relapsed SCLC. Most common side effect is myelo-
supression. See Table 2.
In  a  phase  II  randomized  study  from  Japan, 
60  SCLC  patients  previously  treated  with  platinum-
containing  chemotherapy  were  randomly  assigned Nair et al
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to  amrubicin  (40  mg/m2)  on  days  1–3  or  topotecan 
(1.0 mg/m2) on days 1–5. This treatment gave an   overall 
response rate of 38% vs. 13% with amrubicin and topo-
tecan respectively and in sensitive relapse patients it 
was 53% vs. 21% but it was much lower in refractory 
relapse with 17% vs. 0% respectively. Median PFS for 
amrubicin  and  topotecan  respectively  were  3.5  and 
2.2 months. This study showed amrubicin improved OS 
in Japanese patients though it is noteworthy that dose of 
topotecan was lower than used in other clinical trials.27
In an another phase II randomized study conducted 
in US on 76 SCLC patients who were sensitive to 
first line platinum based therapy were treated with 
amrubicin infusion (40 mg/m2/d) on days one through 
three, every 21 days or topotecan (1.5 mg/m2), on 
days one through five, every 21 days. This study also 
showed a higher ORR among amrubicin compared to 
topotecan, it was 44% vs. 15% (P = 0.021). Median 
survival was 9.2 months vs. 7.6 months, and median 
PFS was 4.5 vs. 3.3 months. Major toxicity included 
grade 3 or 4 neutropenia was 78% and 61% and grade 
3 or 4 thrombocytopenia was 61% and 39% in topo-
tecan and amrubicin group respectively.28
In another phase II study recently published on 
75  patients  with  platinum  refractory  SCLC  who 
were treated with single agent amrubicin ORR was 
21.3% with 1 CR and OS of 6 months with PFS of 
3.2 months. Interestingly, in 43 patients who never 
responded to first line therapy ORR was 16.3%. Grade 
3 or 4 adverse events included neutropenia (67%), 
thrombocytopenia  (41%),  and  anemia  (30%),  with 
febrile neutropenia in 12% of the patients. There was 
no decrease in mean Left ventricular ejection fraction 
(LVEF) with cumulative amrubicin doses exceeding 
750 mg/m2. This was a very promising study show-
ing activity of single-agent amrubicin when used as 
second-line therapy in patients with platinum refrac-
tory SCLC.29 Importantly, no cardio toxicity was seen 
in any of the above mentioned amrubicin trials.
Very recently, a first phase III randomized con-
trolled study by Jotte et al was presented at ASCO 
2011, comparing amrubicin and IV topotecan. This 
study had 637 patients including both refractory and 
sensitive patients to 1st line chemotherapy. ORR was 
31% and 17% for amrubicin and topotecan, respec-
tively (P-0002). OS was 7.5 and 7.8 among each group 
(P-0.17)  and  in  subgroup  analysis  OS  in  sensitive 
patients was 9.2 vs. 10 months (P-0.62) but among 
refractory patients it was 6.2 vs. 5.7 (P = 0.047) with 
18 month OS superior for amrubicin group with 12% 
and 0% for topotecan (P = 0.0006). Major toxicities 
were grade 3 or 4 neutropenia 41% vs. 53%, throm-
bocytopenia 21% vs. 54%, anemia 16% vs. 30% and 
febrile  neutropenia  10%  vs.  4%.  This  study  defi-
nitely demonstrates the benefit of amrubicin, espe-
cially  among  refractory  patients,  with  manageable 
toxicities.67
Topotecan vs. Amrubicin
From all the clinical trials available, we can conclude 
amrubicin has clinical benefits in relapsed SCLC and 
is comparable to topotecan with better reported out-
comes in chemotherapy refractory patients with man-
ageable side effects. No cardio toxicity was seen in 
any of the clinical trials so far conducted. This drug 
is active in refractory patients which is a challenging 
group of patients with dismal prognosis. It would be 
interesting to know if there is additive benefit when 
Table 2. Amrubicin based treatment as second line for small cell lung cancer.
phase, drug Authors number ORR-% TTp-m Os-m TRD
II, amrubicin Onoda65 60 (S+r) S-52 
r-50
S-4.2 
r-2.6
S-11.6 
r-10.3
None
II, amrubicin Ettinger29 75 (r) 21.3 3.2 6 None
II, amrubicin Kato66 35 (S+r) 53 8.8 None
II, amrubicin vs.  
topotecan
Inoue27 60 (S+r) A-38 (53 vs. 17) 
T-13 (21 vs. 0)
A-3.5 
T-2.2
8.1 (9.9 vs. 5.3) 
8.4 (11.7 vs. 5.4)
A-3.4%
II, amrubicin vs.  
topotecan,
Jotte28 76 (S) A-44 
T-15
A4.5  
T3.3
A-9.6 
T-7.6
None
III, amrubicin vs.  
topotecan
Jotte67 637 (S+r) A-31 
T-17
A-4.1 
T-4.0
S-9.2 vs. 10 
r-6.2 vs. 5.7
None
Abbreviations: S, sensitive; r, refractory; w, week; M, month; Orr, over all response rate; TTp, time to progression; TrD, treatment related death; OS, 
overall survival; A, amrubicin; T, topotecan.pharmacotherapies for the treatment of SCLC
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amrubicin is combined with other   chemotherapeutic 
agents especially platinum or topoisomerase inhibitors.
Taxanes as single Agents
The  principal  mechanism  of  action  for  taxanes 
including paclitaxel and docetaxel is the disruption 
of microtubule function. These two drugs have very 
good response rate in many cancers even when used 
as second line or third line treatment. In a phase II 
study on 24 patients with refractory SCLC treated 
with paclitaxel (175 mg/m2) IV every three week had 
ORR of 29% with median OS of 100 days.30 In an 
another study with 93 patients with refractory SCLC 
were treated with higher dose paclitaxel (200 mg/m2) 
every three weeks for up to six cycles. This regimen 
gave ORR of 20% and median TTP and OS of three 
and  four  months  respectively  with  complications 
including febrile neutropenia (23%) and grade 3 or 
4 neuropathy (8%), but no toxic deaths. This was a 
promising  single  agent  study  in  chemo  refractory 
patients but had a high incidence of febrile neutro-
penia.31    Docetaxel  has  been  studied  in  previously 
treated SCLC patients with a partial response of 25%, 
neutropenia was the significant toxicity.32
Taxanes in combination
paclitaxel and carboplatin
In a phase II study involving 35 SCLC patients refrac-
tory to cyclophosphamide, doxorubicin, and etopo-
side (CDE), combination of carboplatin and paclitaxel 
showed a response rate of 73.5% with two patients 
achieving CR. Paclitaxel was given at standard dose 
(175 mg/m2) and carboplatin at area under the curve 
of 7 every three weeks for five cycles. Main toxicity 
was hematological with grade 3 or 4 leucopenia in 
33%,  thrombocytopenia  in  34%,  and  anemia  was 
17% with low grade neuropathy about 69%, no toxic 
death was reported. Median time to progression and 
OS were 21 and 31 weeks respectively. This study 
was very encouraging among CDE refractory patients 
with very high response rate.33
paclitaxel and doxorubicin
Paclitaxel  (175  mg/m2)  combined  with  doxorubi-
cin  (40  mg/m2)  was  studied  in  46  relapsed  SCLC 
patients, and gave ORR of 41% with three complete 
remissions, of responders 14% were chemotherapy 
refractory patients and 52% were sensitive patients. 
Remarkable side effects included Grade 3 or 4   emesis 
and    neutropenia  in  11%  and  80%  of  the  patients 
respectively and 20% were hospitalized for neutro-
penic fever, one patient had grade 3 cardio toxicity 
and another one had grade 4 myalgia.34 Though this 
combination had decent response, side effects were 
high, and many of our patients may not tolerate.
paclitaxel and gemcitabine
Results from a phase II study on 31 patients with 
relapsed SCLC treated with paclitaxel (175 mg/m2) 
on day one and gemcitabine (1250 mg/m2) on days 
one and eight showed ORR for chemotherapy sensi-
tive disease was 60% and for refractory disease was 
40%. Treatment was well tolerated with grade 3 or 
4 neutropenia occurred in 11% of the patients. The 
median  duration  of  response  was  five  months  and 
median time to progression seven month respectively. 
Non-hematological toxicity was very mild.35 Gemcit-
abine and docetaxel combination was tried on 22 pre-
viously treated patients with SCLC in a phase II trial 
but did not have any PR or CR.37
paclitaxel, ifosfamide, and cisplatin
A phase II trial with 30 patients who had either pro-
gressed or relapsed after carboplatin and etoposide 
were treated with an intense regimen of paclitaxel 
(175 mg/m2) on day one, ifosfamide (5 g/m2) on days 
one and two, and cisplatin (100 mg/m2) divided over 
days one and two every 21 days with growth factor 
support.  Overall  response  rate  was  73%  including 
8 CR and 1-year survival rate was 12%. Grade 3 and 
4 neutropenia and thrombocytopenia was seen in 73% 
and 27% patients respectively with 18% had febrile 
neutropenia 23% had grade 3 nausea and vomiting 
but overall no treatment-related deaths occurred.36
Irinotecan
Irinotecan is a topoisomerase Iinhibitor and as a single 
agent has modest response in SCLC.38–40 It has also 
been studied in combination with other agents.
Irinotecan and etoposide
Masuda et al evaluated topotecan and etoposide com-
bination  in  25  patients  with  refractory  or  relapsed 
SCLC. Irinotecan was given (70 mg/m2) IV on days 
one, eight and fifteen and etoposide (80 mg/m2) IV 
on days 1–3 every four weeks. Overall response rate Nair et al
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was 71% with three patients achieving with median 
response   duration and survival about 4.5 and 9 months 
respectively. Major toxicity was grade 3 and 4 neutro-
penia and thrombocytopenia which were seen in 56% 
and 20% of the patients, respectively. One patient 
died from treatment related death due to severe myelo-
suppression.41  Interestingly,  all  these  patients  were 
exposed to etoposide previously and most likely a 
synergistic action contributed to this response.
Irinotecan and platinum Based 
combinations
Irinotecan and cisplatin
Irinotecan and cisplatin are reported to act synergisti-
cally. Nakanishi et al conducted a phase II trial combin-
ing cisplatin and irinotecan in patients with refractory 
SCLC. They had 21 patients who had not responded 
to prior platinum based chemotherapy. Both cisplatin 
(30 mg/m2) and irinotecan (60 mg/m2) were adminis-
trated on days one, eight, and fifteen and the regimen 
was repeated every 28 days. ORR was 29% and the 
median survival time for all patients was 32 weeks. One 
and two year survival rates were 43% and 11%, respec-
tively. Major toxicity included grade 3 or 4 leucopenia, 
anemia, thrombocytopenia, and diarrhea was seen in 
43%, 38%, 19%, and 38% of patients, respectively.42
This same regimen was tried in another study by 
Masahiro et al. But coinciding with the infusion and for 
four days thereafter the anti diarrheal program was 
given using orally administered sodium bicarbonate, 
magnesium oxide and basic water. Twenty-five patients 
who had had prior treatments with etoposide and plati-
num containing regimens (16 were refractory patients) 
ORR was 80% and the median time to progression and 
OS were 3.6 and 7.9 months, respectively. Main Toxic-
ity was grades 3 or 4 neutropenia seen in 36% of the 
patients, with one febrile neutropenia and grade 3 diar-
rhea occurred in only 8% of patients, this was better due 
to the anti diarrheal regime.43 These two studies pro-
vide valuable information that weekly irinotecan plus 
cisplatin, are well tolerated and work synergistically in 
combination with manageable toxicities and is active in 
refractory or relapsed, especially platinum refractory.
Irinotecan in combination  
with cisplatin and etoposide
Goto et al did a multi institutional phase II study involv-
ing 40 patients with chemotherapy sensitive relapsed 
SCLC using irinotecan in combination with cisplatin 
and etoposide (PEI). All 40 patients had previously been 
treated using platinum based chemotherapy and eight 
(20%) of these patients also received thoracic radio-
therapy. They received cisplatin (25 mg/m2) weekly 
for nine weeks, etoposide (60 mg/m2) for three days 
on weeks 1, 3, 5, 7, and 9 and irinotecan (90 mg/m2) 
on weeks 2, 4, 6, and 8 with granulocyte colony stim-
ulating factor support and ORR was 78% including 
five patients with CR. The median survival time was 
11.8 months, and the estimated 1-year survival rate was 
49%. Grade 3 or 4 neutropenia, and thrombocytopenia 
were observed in 73% and 33% of the patients, respec-
tively.44 This was a remarkable response rate but the trial 
was done in chemotherapy sensitive patients and most 
of them had good PS whereas in our everyday prac-
tice many patients with relapsed SCLC have poor PS 
and may not be able to tolerate this much side effects.
Irinotecan and carboplatin
A phase II study reported by Hirose et al used irinotecan 
and carboplatin in 24 patients with relapsed small cell 
lung cancer. Patients were treated every three weeks 
with carboplatin (AUC 5) plus irinotecan 50 mg/m2 on 
days one and eight. Overall response rate of  68.2%, but 
most (92.3%) were chemotherapy sensitive. The median 
survival time was 194 days. The median survival time 
did not differ significantly between patients with sensi-
tive disease (245 days) and those with refractory disease 
(194 days, P = 0.88). Toxicities included Grade 3–4 
neutropenia (63%), thrombocytopenia (58%), anemia 
(67%), Grade 3 diarrheas (21%) and infections (13%).45 
Another recent phase II study by Chen et al using irino-
tecan and carboplatin in relapsed small cell lung cancer, 
had 80 patients and showed 50% response rate and 
OS of ten months, Major toxicities were grade 3 or 4 
neutropenia (54%), thrombocytopenia (22%), anemia 
(13%), diarrhea (22%), and nausea or emesis (11%) 
and three neutropenic sepsis.55
Other combinations of Irinotecan
Irinotecan and gemcitabine
A phase II study evaluated the efficacy and safety 
of  the  irinotecan  and  gemcitabine  combination  in 
patients with relapsed and refractory small cell lung 
cancer. Gemcitabine (1000 mg/m2) was administered 
IV followed by irinotecan (100 mg/m2) IV both on 
days one and eight every 21 days. OS rates were 31% pharmacotherapies for the treatment of SCLC
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in   sensitive and 11% in refractory patients. Median 
survival and progression free survival time were 7.1 
versus 3.5 months, and 3.1 versus 1.6 respectively. 
Primary grade 3 or 4 toxic effects for chemo sensitive 
and refractory patients were neutropenia (36% ver-
sus 43%) and thrombocytopenia (36% versus 26%).46
Liposomal doxorubicin in combinations 
with irinotecan
Liposomal doxorubicin is a novel formulation of dox-
orubicin, in which the drug is, encapsulated in polyeth-
ylene glycol coated liposomes which results in better 
uptake in cancer cells as opposed to normal cells. 
Xendils et al did a phase II trial using pegylated lipo-
somal doxorubicin in combinations with irinotecan as 
second line therapy in refractory SCLC. 31 patients 
with early relapse after first-line therapy with cisplatin 
and etoposide were treated with pegylated liposomal 
doxorubicin (15 mg/m2) and irinotecan (125 mg/m2)
on days one and fifteen repeated every 28 days. Main 
toxicities  were  grade  3  neutropenia  and  fatigue  in 
6.5% and 23% of patients respectively. Though it was 
well tolerated, activity was only modest; with ORR 
of 12.9% with OS of 3.16 months.47 Another study of 
single agent pegylated liposomal doxorubin also did 
not show any response in relapsed SCLC.48
Combination of cisplatin, ifosfamide,  
and irinotecan
Fujita et al studied combination of cisplatin, ifosfamide, 
and irinotecan with G-CSF support in eighteen patients 
with  refractory  or  relapsed  small-cell  lung  cancer. 
  Cisplatin (20 mg/m2) and ifosfamide (1.5 g/m2) were 
administered on days 1–4, and irinotecan (60 mg/m2) 
were administered on days one, eight, and fifteen given 
every four weeks. Overall response rate and survival 
time were 94.4% and eleven months respectively. Sig-
nificant toxicities including grade 4 neutropenia and 
thrombocytopenia seen in 61% and 33% of the patients 
respectively and no treatment related death occurred in 
this group of patients who received this strong three 
drug combination.49 This study is very encouraging with 
very good overall response, and manageable toxicity.
Other combinations
CAv regimen
Combinations  of  cyclophosphamide,  doxorubicin, 
and vincristine can be used with modest activity in 
patients  who  have  had  platinum  based  treatment. 
This was studied by Shepherd et al in 29 patients who 
received CAV after their tumors failed to respond to 
or  relapsed  after  etoposide  and  cisplatin  (VPP)  or 
etoposide and carboplatin (VPC). Thirteen patients 
were treated following failure to respond to VPP or 
VPC and sixteen at the time of relapse. There were 
three CR and five PR and ORR was 28%. This study 
demonstrates that CAV has modest activity follow-
ing  failure  of  platinum  based  chemotherapy.50  As 
mentioned earlier, another large randomized trial has 
already shown equal efficacy of single agent topote-
can as compared to CAV with less toxicity thus limit-
ing use of CAV in routine clinical practice.9
CODE regimen
This study was undertaken by Kubota et al to deter-
mine the activity and toxicity of dose intensive weekly 
chemotherapy (cisplatin, vincristine, doxorubicin, and 
etoposide  (CODE  regimen)  in  seventeen  recurrent 
SCLC patients. All seventeen patients had been heav-
ily pretreated with some form of cisplatin-based com-
bination chemotherapy. This regimen gave an overall 
response of 88.2% including 29% CR rate. Myelosup-
pression was very common with grade 4 leucopenia in 
76% of the patients but no treatment related deaths.51
vIp regimen
Faylona et al did a phase II study to determine the activ-
ity and toxicity of oral etoposide, with IV ifosfamide, 
and cisplatin in previously treated, recurrent SCLC. 
46 patients were enrolled to receive oral etoposide 
(37.5 mg/m2/d) for 21 days, ifosfamide (1.2 g/m2/d) 
for four days, and cisplatin (20 mg/m2/d) for four days, 
repeated every 28 days. Objective response was 55% 
including 14% CR. Median PFS and over all median 
survival were 20 and 29 weeks respectively. There 
were six treatment related deaths most of them due to 
sepsis. Though response rate was good but this regi-
men had significant treatment related side effects.52
These  aggressive  combinations  work  in  second 
line setting but at the expense of high toxicity.
Oral etoposide
Although most patients receive IV etoposide, there 
is  some  evidence  that  oral  etoposide  can  be  an 
option as well. In a phase II study by Einhorn et al, 
26 previously treated patients with refractory small Nair et al
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cell  lung  cancer  were  given  daily  oral  etoposide 
(50 mg/m2/d), 25 patients had prior exposure to cis-
platin plus etoposide and fourteen had prior therapy 
with  CAV  (cyclophosphamide,  doxorubicin,  and 
vincristine). Interestingly, their overall response was 
23% including one patient who had CR.53 Johnson 
et al also looked into this idea as well. Twenty two 
patients (most of them received etoposide IV as part 
of  induction  treatment)  with  recurrent  small-cell 
lung cancer were treated with single agent etopo-
side  (50  mg/m2/d)  by  mouth  for  21  consecutive 
days repeated every 28 days depending on tolerance 
and response. ORR was 36% and median survival 
was more than 3.5 months and response duration of 
four months. Grade 3 or 4 neutropenia and throm-
bocytopenia were seen 18% and 25% of the patients 
respectively.  There  were  two  toxic  deaths  due  to 
sepsis  and  five  patients  required  hospitalizations 
for neutropenia  and  fever.54 This  is  an  impressive 
response, in those patients receiving oral etoposide 
after  previous  exposure  to  IV  etoposide,  but  side 
effects are concerning.
experimental Treatments
As we learn more about various neoplasms at the 
molecular level, specific targeted therapies are being 
developed. These include tyrosine kinase inhibitors, 
apoptotic  stimulants  and  anti  angiogenesis  agents 
alone  or  in  combinations,  but  so  far  none  of  the 
treatments have provided clinical benefit in terms of 
symptom relief or survival in SCLC.56–60 Picoplatin 
is a new platinum compound designed to overcome 
platinum resistance and has shown less neurotoxicity 
and nephrotoxicity than other platinum agents. But a 
randomized control study with picoplatin versus best 
supportive  care  in  chemo  sensitive  and  refractory 
patients, failed to show any improvement in overall 
survival.61,62
conclusion
Incidence of SCLC is certainly decreasing, due to 
decreasing number of smokers and there is a slight 
increase in overall survival over last few years as 
noted from most recent SEER data. Our understand-
ing of this cancer has improved over the last few 
years but this understanding has not translated into 
improved treatment regimens or finding new drugs 
with  better  outcome.  Response  to  1st  line  chemo-
therapy and the duration of the response are the most 
important   factors in overall survival and response to 
second line treatment. Though we have many drugs 
that have clinical activity not many large random-
ized  control  studies  have  been  done  except  in  the 
case of topotecan and amrubicin. Combinations of 
drugs have shown significant response rate but their 
use  in  previously  pre-treated  patients  with  overall 
poor clinical condition has not been feasible, though 
in selected patients combinations can be considered 
especially  in  chemo  refractory  patients.  Topotecan 
is current standard of care in chemosenstive patients 
and its use is approved in US and other parts of the 
world. Amrubicin is only approved in Japan and fur-
ther studies are ongoing. It has shown good response 
even in chemo refractory patients in phase II and III 
trials. It would be interesting to know if combination 
treatment with amrubicin gives better response and 
survival as compared to single agent. New clinical tri-
als are a must, especially combinations to overcome 
chemo resistance of these tough to treat relapse or 
refractory small cell lung cancer.
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